Haemophilus Infections
9
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
78%
7 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (9)
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination
Immunogenicity and Safety of Pentaxim in South African Infants
Immunogenicity and Safety of Pentaxim™ in an Indian Population
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand